NCI recently announced a master plan for its $500 million Childhood Cancer Data Initiative, a pilot project designed to set the stage for building a publicly accessible, comprehensive data federation for all cancers (The Cancer Letter, Dec. 4, 2020).
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
